There are mixed emotions on how shareholders feel about the

New Post Public Reply Private Reply Replies (5) Message Board
Splithappens Fiat123 #63930
804
There are mixed emotions on how shareholders feel about the management of SFOR. We are now over 3 Billion OS,to be exact, the latest update is now 3,033,996,043 OS as per otcmarkets.com. It truly sucks and is concerning.

BUT, acording to Kays last tweet we will be in the black by Aug. this year. My understanding is that there sould be profits for the year from that point on.

SFOR's net loss for 2018 was, "We have yet to establish any history of profitable operations. For the year ended December 31, 2018, the Company incurred a net loss of $3,837,249", as per the 2019 10k filed about 10 months ago.

So, is it possable Kay will receive enough money to cover of our expenses for most of the year 2020 by Aug. If so, with increasing revs. each month, can we expect to net a PROFIT of $1,000,000-1,500,000 for 2020. Plus $9 Milly for patents (if purchased in 2020). Show me a single OTC company on the OTC trading this cheap with seven figure profits.

Will 2021 be $2-$4 Million net profit year?

And so on...

My understanding is that the numbers above do not include new deals not yet disclosed.

As usual with SFOR (not the typical otc stock) there is alot to consider, pros and cons (this is true with all companies).

I am willing to endure a little more pain over the weeks and possably months to come, as long as the pros start to overpower the cons. The most important pro being Revs (may take months to learn about through Q's and k). As the public info becomes avail. shareholders will be influenced to buy or sell. Hopefully more buys than sells.

I wont bash (unless he/she is a blatent crook like Madolf) or praise CEO's, their job is not easy. We all can be bashed or praised for things we do on a daily basis.

Sorry for rambling.

IMO

GLTA


Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

TSA PreCheck Study Reveals Time Savings and Travel Insights

Updated Category News Views 379

Understanding TSA PreCheck's Impact on Travelers The latest survey reveals some interesting insights about TSA PreCheck, especially concerning the time savings that members experience at security checkpoints. Conducted by Upgraded Points, this enlightening study assessed the experience of over 1,500 travelers to evaluate the true advantages of holding a TSA PreCheck...

Continue Reading
Intermap Technologies Enhances Geospatial Solutions with New Offering

Updated Category News Views 217

Intermap Technologies Announces New Prospectus Supplement DENVER – Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF), a recognized leader in 3D geospatial products and intelligence solutions, has filed a prospectus supplement in the context of a strategically planned public offering. This initiative signifies a promising step forward, with the company aiming to...

Continue Reading
Urgent Investor Notice: Humacyte Legal Claims Investigation

Updated Category News Views 94

Critical Deadline for Humacyte Investors Approaches As time runs short, investors in Humacyte, Inc. (NASDAQ: HUMA) should pay attention. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims on behalf of investors who have suffered losses exceeding $75,000 due to potential violations in federal securities laws. Understanding Your...

Continue Reading
Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab

Updated Category News Views 226

Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab Natalie Bartholomew, a highly recognized advocate for women in financial services, will be the featured speaker for the Women in Banking session at Alkami Co:lab 2026. Her expertise and passion are expected to inspire attendees and foster discussions around women's roles in the financial sector. Alkami...

Continue Reading
Investors Anticipate Strong Earnings from OPAL Fuels Soon

Updated Category News Views 161

OPAL Fuels Earnings Report Insights OPAL Fuels OPAL is preparing to release its quarterly earnings report soon, and investors are keenly interested in the results. As the anticipated date for this report approaches, it is essential for investors to stay informed and understand what the expectations are. Projected Earnings Overview Analysts project that OPAL Fuels will...

Continue Reading